Treatment of Bartter's Syndrome With Indomethacin

Garin, Eduardo H.

doi:10.1001/archpedi.1980.02130150016005

Cited by 2 publications

(1 citation statement)

References 17 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were confirmed by many investigators, and treatment with PG synthase inhibitors including indomethacin, aspirin and ibuprofen became immensely popular in both adult and pediatric nephrology. Proesmans et al in 1977 were the first to show that indomethacin was very effective in two unrelated pediatric patients with BS, and many more papers followed to confirm these findings [10,11].…”

Section: Third Hypothesismentioning

confidence: 99%

Threading through the mizmaze of Bartter syndrome

Proesmans

2006

Pediatr Nephrol

View full text Add to dashboard Cite

The story, described here in detail, started in 1962 with the publication of a seminal paper by Frederic Bartter et al. in the December issue of the American Journal of Medicine. The authors reported two pediatric patients with hitherto undescribed features, namely growth and developmental delay associated with hypokalemic alkalosis and normal blood pressure despite high aldosterone production. It soon became clear that this condition was not so exceptional. The syndrome named after Bartter was actually identified in children as well as in adults, females as well as males and in all five continents. It took almost four decades to clarify the exact nature of the disease. Bartter disease is an autosomal recessive disorder with four genotypes and mainly two phenotypes. Moreover, there are acquired secondary forms of Bartter syndrome as well as pseudo-Bartter syndromes. The history demonstrates the power of genetics but also illustrates the fundamental and irreplaceable contributions from nephrologists and renal physiologists.

show abstract

Section: Third Hypothesismentioning

confidence: 99%

Threading through the mizmaze of Bartter syndrome

Proesmans

2006

Pediatr Nephrol

View full text Add to dashboard Cite

show abstract

Advances in the development of novel compounds targeting cation-chloride cotransporter physiology

Delpire

2021

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

For about half a century, the pharmacology of electroneutral cation-chloride cotransporters has been dominated by a few drugs that are widely used in clinical medicine. Because these diuretic drugs are so good at what they do, there has been little incentive in expanding their pharmacology. The increasing realization that cation-chloride cotransporters are involved in many other key physiological processes and the knowledge that different tissues express homologous proteins with matching transport functions have rekindled interest in drug discovery. This review summarizes the methods available to assess the function of these transporters and describe the multiple efforts that have made to identify new compounds. We describe multiple screens targeting KCC2 function and one screen designed to find compounds that discriminate between NKCC1 and NKCC2. Two of the KCC2 screens identified new inhibitors that are 3-4 orders of magnitude more potent than furosemide. Additional screens identified compounds that purportedly increase cell surface expression of the cotransporter, as well as several FDA-approved drugs that increase KCC2 transcription and expression. The technical details of each screen biased them towards specific processes in the life cycle of the transporter, making these efforts independent and complementary. In addition, each drug discovery effort contributes to our understanding of the biology of the cotransporters.

show abstract

Treatment of Bartter's Syndrome With Indomethacin

Cited by 2 publications

References 17 publications

Threading through the mizmaze of Bartter syndrome

Threading through the mizmaze of Bartter syndrome

Advances in the development of novel compounds targeting cation-chloride cotransporter physiology

Contact Info

Product

Resources

About